Cholera Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Cholera – Pipeline Review, H1 2015” to its store. The report provides an overview of the Cholera’s therapeutic pipeline.

Cholera Therapeutic Pipeline Market

Cholera Therapeutic Pipeline Market

The report “Cholera – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Cholera. Cholera is a bacterial disease usually spread through contaminated water. Cholera causes severe diarrhea and dehydration. Left untreated, cholera can be fatal in a matter of hours, even in previously healthy people. Common symptoms of cholera include vomiting, diarrhea, and muscle cramps. Although the signs and symptoms of this condition are generally mild, about 1 infected person out of 20 will have severe symptoms, such as increased heart rate, coma, and dehydration. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cholera-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Cholera and special features on late-stage and discontinued projects. Companies discussed in this Cholera – Pipeline Review, H1 2015 report include Beijing Minhai Biotechnology Co., Ltd, Napo Pharmaceuticals, Inc. and PaxVax.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AKT-10082, cholera (trivalent) vaccine, crofelemer DR, Peptide for Cholera and Guillain-Barre Syndrome and PXVX-0200. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310177 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial; Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum; Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study; May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference; Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned; Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine; Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting; Mar 19, 2012: FDA Accepts PaxVax's IND For Single-Dose Oral Cholera Vaccin.

List of Tables
Number of Products under Development for Cholera, H1 2015 7
Number of Products under Development for Cholera - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 16
Cholera - Pipeline by Napo Pharmaceuticals, Inc., H1 2015 17
Cholera - Pipeline by PaxVax, H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 22
Number of Products by Stage and Molecule Type, H1 2015 24
Cholera Therapeutics - Recent Pipeline Updates, H1 2015 31
Cholera - Dormant Projects, H1 2015 35
Cholera - Discontinued Products, H1 2015 36

List of Figures
Number of Products under Development for Cholera, H1 2015 7
Number of Products under Development for Cholera - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22
Number of Products by Top 10 Molecule Types, H1 2015 23
Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

Explore more reports on Infectious Diseases Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website